International Symposium on Inhalational Drug R&D
Conference overview
The prevalence of respiratory diseases is continuing to increase globally, and according to the data disclosed in the Lancet, respiratory diseases have become the third largest chronic disease in China. According to the statistics of the World Health Organization, respiratory diseases, mainly asthma and chronic obstructive pulmonary disease (COPD), have become one of the top five causes of death both in China and worldwide. With China's diagnosis and treatment rate and control rate gradually moving closer to the United States, the patient base continues to accumulate, the global asthma and COPD drug market sales in 2022 reached 87.403 billion yuan, with the proportion of inhaled preparations in respiratory system drugs steadily increasing, the market is expected to reach 106.967 billion yuan by 2028. The compound annual growth rate (CAGR) was 3.46%.
The markets for inhalational drugs are supposed to grow rapidly over the next decade as the incidence of COPD, asthma and other respiratory diseases keeps increasing. However, due to the high technical barriers of inhalational drugs on R&D, especially manufacturing and quality control, safety assessment and regulatory approval rate, it is difficult to see the "patent cliff". Even under this condition, we have seen the thriving R&D in inhalational drugs in China recent years. How to adopt the new technology rapidly and how to prompt the R&D process and get breakthrough have been the focus of the industry and research institutions.
The “International Symposium on Inhalational Drug R&D" to be held online on September 9-10 is aimed at providing an international platform for the discussion of inhalational drug R&D, specifically focus on Toxicology, BE Studies, Applied Pharmacology and Clinical Research. This symposium will gather the outstanding professionals including government regulatory reviewers (USFDA and China NMPA), research scientists, medical doctors and practitioners, industrial experts and students to share their ideas and their experiences.
Conference organization
Committee of Respiratory Toxicology, Chinese Society of Toxicology
JOINN Laboratories (China) Co., Ltd.
Taicang Science and Technology Association
Taicang Biomedical Industry Association
JOINN Laboratories (Suzhou) Co., Ltd.
Meeting time
Sep. 8-10, 2023
Agenda
|
Date |
Time |
Topic |
Speaker |
|
9/9/2023 |
08:00-08:30 |
Sign in |
|
|
08:30-09:00 |
Opening Ceremony |
||
|
09:00-09:45 |
Keynote Speech |
To be confirmed Academician of CAE Member |
|
|
09:45-10:30 |
FDA technical and regulatory considerations for the review of inhaled drugs |
Dr.Luqi Pei Senior Pharmacologist, CDER, FDA |
|
|
10:30-10:40 |
Coffee Break |
||
|
10:40-11:10 |
Main points of evaluation and review of inhaled drugs |
To be confirmed |
|
|
11:40-12:15 |
Quality evaluation and selection of atomizer and atomizing inhalant |
To be confirmed China National Institute for Food and Drug Control |
|
|
12:15-13:30 |
Lunch |
|
|
|
9/9/2023 |
13:30-14:00 |
Health hazards of electronic cigarette and research progress |
Zhiwei Sun |
|
14:00-14:30 |
To be confirmed |
Qiangmin XIe |
|
|
14:30-15:00 |
Drug R&D clinical development for first-in-class inhalation drug |
Dr. Jin Yang China Pharmaceutical University, NMPA Invited Reviewer |
|
|
15:00-15:30 |
R&D for Inhalation drug |
Dr. Wenqing Liang Chairman of CF PharmTech, Inc. |
|
|
15:30-15:40 |
Coffee Break |
||
|
15:40-16:10 |
Characteristics and practice of non-clinical studies on respiratory system drug delivery |
Dr. Haifei Zhang S.V.P., Chief of Ophthalmic Laboratory, JOINN Laboratories |
|
|
16:10-16:40 |
Formulation and process development and research of inhaled drug |
Dr. Shuguang Hou Vice Chairman of IDDA, CEO of Sichuan Purity Pharmaceutical Co., Ltd |
|
|
16:40-17:10 |
Pathology Research on inhalation Studies |
Mu Du |
|
|
17:10-17:40 |
Research progress and application of PBPK model for inhaled preparations based on simulation |
Zhenbo Tong |
|
|
17:40-18:10 |
Study on nebulized human nanoantibodies against COVID-19 |
Tianlei Ying Professor, School of Basic Medicine, Fudan University, Cheung Kong Scholars Distinguished Professor, Ministry of Education |
|
|
18:30-20:00 |
Dinner |
||
|
10/9/2023 |
09:00-09:30 |
Status of chronic obstructive pulmonary disease and the treatment of inhaled preparations |
Wenju Lu |
|
08:30-09:00 |
To be confirmed |
Qiangming Xie Professor of Pharmacology, Zhejiang University School of Medicine, Deputy Director of Zhejiang Respiratory Drug Research Laboratory, State Food and Drug Administration |
|
|
11:15-11:45 |
Research and development status and trend of inhalation preparation |
Dr. Fang Jin CSO of Joincare Pharmaceutical Group Industry Co., Ltd |
|
|
10:00-10:15 |
Coffee Break |
||
|
10:15-10:45 |
Development and progress of inhaled nano antibody drugs |
Peng Qiao |
|
|
14:30-15:00 |
Selection and pharmacodynamic evaluation of respiratory disease models |
Dongkai Wu |
|
|
10:45-11:15 |
Design and implementation of bioequivalence study scheme for oral inhalation preparations |
Dr. Qing He Director of Drug Clinical Trial Institution Office, Wuxi People's Hospital |
|
|
11:10-11:40 |
PD research on inhalation drugs |
Dr. Zhaolong Cao Chief physician, Department of Respiratory Medicine, Peking University People's Hospital |
|
|
11:40-13:00 |
Lunch |
||
Conference guests
Conference sponsorship
Venue
Four Points by Sheraton Taicang
Hotel phone：400-151-2828
hotel's address：No. 288 Shanghai East Road, Taicang Suzhou, Jiangsu 215400
Conference traffic
Conference accommodation
contact us
Sign up now
Scan left QR code to complete registrationRegistration process：